Treatment problem of anephric patients with Wilms tumor
https://doi.org/10.21682/2311-1267-2020-7-2-120-5
Abstract
Bilateral nephroblastoma is rare and is about 5 % of the total number of patients. The modern strategy of treatment children with bilateral Wilms tumor requires a comprehensive approach. An important task is to preserve as much of the renal parenchyma as possible, which will be sufficient for normal kidney function and development of the child. However, in subtotal kidney damage organ-preserving treatment is not always possible. In this case, the only curative option is bilateral nephrectomy followed by continuous renal replacement therapy. To date, the literature describes isolated cases of adjuvant chemotherapy in children on peritoneal dialysis. The article presents a clinical case of specific therapy with topotecan for a child after bilateral nephrectomy, a carrier of peritoneal dialysis catheter on the background of progression of the underlying disease.
About the Authors
R. I. IzmozherovaRussian Federation
R.I. Izmoherova, Clinical Resident of Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
S. A. Kuleva
Russian Federation
Dr. of Sci. (Med.), Head of Pediatric Oncology Department, Leading Researcher of the Research Department of Innovative Therapeutic Oncology and Rehabilitation Methods, Professor of the Training and Methodology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
S. V. Ivanova
Russian Federation
Cand. of Sci. (Med.), Pediatric Oncologist of Pediatric Oncology Department, Researcher of the Research Department of Innovative Therapeutic Oncology and Rehabilitation Methods
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
E. D. Gumbatova
Russian Federation
Pediatric Oncologist of Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
E. M. Senchurov
Russian Federation
Pediatric Oncologist of Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
A. I. Osipov
Russian Federation
Cand. of Sci. (Med.), Associate Professor, Pediatric Urologist-Andrologist, Head of 1st Surgical Department
2 Litovskaya St., S.-Petersburg, 194100, Russia
S. A. Sarychev
Russian Federation
Pediatric Urologist-Andrologist 1st Surgical Department
2 Litovskaya St., S.-Petersburg, 194100, Russia
A. G. Trofimova
Russian Federation
Nephrologist Dialysis Department
2 Litovskaya St., S.-Petersburg, 194100, Russia
N. D. Faseeva
Russian Federation
Cand. of Sci. (Med.), Pediatric Oncologist of Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
E. A. Mikhailova
Russian Federation
Clinical Resident of the Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
K. M. Borokshinova
Russian Federation
Clinical Resident of Pediatric Oncology Department
68 Leningradskaya St., Pesochny, Saint Petersburg, 197758, Russia
References
1. Kozlova V.M., Kazubskaya T.P., Sharoev T.A., Kirichenko O.P., Koshechkina N.A., Moiseenko E.I. Hereditary forms of Wilms tumor and their genetic counseling. Bulletin of the Federal State Budgetary Institution “N.N. Blokhin Russian Scientifi c Center” = Journal of N.N. Blokhin Russian Cancer Research Center 1998;9(2):6–12. (In Russ.)
2. Lugtenberg R.T., Cransberg K., Loos W.J., Wagner A., Alders M., van den Heuvel-Eibrink M.M. Topotecan distribution in an anephric infant with therapy-resistant bilateral Wilms tumor with a novel germline WT1 gene mutation. Cancer Chemother Pharmacol 2008;62(6):1039–44. doi: 10.1007/s00280-008-0694-x.
3. Ghanem M.A., van Steenbrugge G.J., Nijman R.J., van der Kwast T.H. Prognostic markers in nephroblastoma (Wilms’ tumor). Urology 2005;65(6):1047–54. doi: 10.1016/j.urology.2004.12.005.
4. Little S.E., Hanks S.P., King-Underwood L., Jones C., Rapley E.A., Rahman N., Pritchard-Jones K. Frequency and heritability of WT1 mutations in nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study Group Study. J Clin Oncol 2004;22(20):4140–6. doi: 10.1200/JCO.2004.02.136.
5. Soff er S.Z., Kim E., Moore J.T., Huang J., Yokoi A., Manley C., O’Toole K., Middlesworth W., Stolar C., Yamashiro D., Kandel J. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg 2001;36(12):1781–4. doi: 10.1053/jpsu.2001.28823.
6. Dzhumabaeva B.T., Biryukova L.S. Nephrotoxicity of anticancer drugs, dose adjustment in patients with lymphoproliereratative and oncological diseases associated with renal failure. Gematologiya i transfuziologiya = Hematology and Transfusiology 2015;60(4):30–5. (In Russ.)
Review
For citations:
Izmozherova R.I., Kuleva S.A., Ivanova S.V., Gumbatova E.D., Senchurov E.M., Osipov A.I., Sarychev S.A., Trofimova A.G., Faseeva N.D., Mikhailova E.A., Borokshinova K.M. Treatment problem of anephric patients with Wilms tumor. Russian Journal of Pediatric Hematology and Oncology. 2020;7(2):120-125. (In Russ.) https://doi.org/10.21682/2311-1267-2020-7-2-120-5